E-resources
-
Cooper, David A; Steigbigel, Roy T; Gatell, Jose M; Rockstroh, Jurgen K; Katlama, Christine; Yeni, Patrick; Lazzarin, Adriano; Clotet, Bonaventura; Kumar, Princy N; Eron, Joseph E; Schechter, Mauro; Markowitz, Martin; Loutfy, Mona R; Lennox, Jeffrey L; Zhao, Jing; Chen, Joshua; Ryan, Desmond M; Rhodes, Rand R; Killar, John A; Gilde, Lucinda R; Strohmaier, Kim M; Meibohm, Anne R; Miller, Michael D; Hazuda, Daria J; Nessly, Michael L; DiNubile, Mark J; Isaacs, Robin D; Teppler, Hedy; Nguyen, Bach-Yen
The New England journal of medicine, 07/2008, Volume: 359, Issue: 4Journal Article, Web Resource
In subgroups of two phase 3 studies, patients with high-risk features for failure of antiretroviral therapy, such as a low CD4 count, high base-line level of human immunodeficiency virus (HIV) type 1 RNA, or unfavorable genotypic or phenotypic sensitivity score, raltegravir was superior to placebo in terms of a virologic response at 48 weeks. However, among these patients, in whom antiretroviral therapy had been used previously, 23% of raltegravir recipients had virologic failure by 48 weeks. In patients with high-risk features for failure of antiretroviral therapy, raltegravir was superior to placebo in terms of a virologic response at 48 weeks. However, among these patients, in whom antiretroviral therapy had been used previously, 23% of raltegravir recipients had virologic failure by 48 weeks. Despite the substantial decrease in mortality and morbidity rates associated with highly active antiretroviral therapy over the past decade, there is still a substantial need for effective antiretroviral drugs for patients infected with resistant human immunodeficiency virus type 1 (HIV-1). 1 , 2 The majority of licensed antiretroviral drugs belong to three classes targeting either the HIV-1 protease or reverse transcriptase, and considerable cross-resistance exists among drugs within each class. 3 , 4 In patients with resistant virus, use of antiretroviral agents from new classes offers considerable potential benefit because of the absence of cross-resistance. 5 – 7 HIV-1 integrase represents a new therapeutic target. 8 , . . .
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.